Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +30.88%
#3 Cysic Cysic +23.33%
#4 Fabric Protocol Fabric Protocol +19.88%
#5 Nockchain Nockchain +19.24%
#6 Bedrock Bedrock +18.65%
#7 Victoria VR Victoria VR +17.20%
#8 Velvet Velvet +17.00%
#9 Fake World Assets Fake World Assets +16.33%
#10 Tutorial Tutorial +11.41%
Coin of the day
EXOD EXOD
設定
言語
日本
通貨
USD
テーマ
Adiuvo Investments S.A. Adiuvo Investments S.A.

Adiuvo Investments S.A.

ADV
株式のランク #37492
Adiuvo Investments S.A. operates as a venture capital firm, deploying capital... Adiuvo Investments S.A. operates as a venture capital firm, deploying capital across the entire spectrum of business development, from initial incubation and seed funding to supporting early-stage, startup, and growth-phase companies. Its primary investment focus lies in the medical devices, digital health, and nutraceuticals sectors, specifically targeting opportunities within Poland. The firm typically commits up to €3 million (approximately $3.35 million) per venture, with an intended holding period of three to five years. All investments are made directly from Adiuvo's own balance sheet. Established in 2013, the company maintains its headquarters in Warsaw, Poland.
株価
$0.12668455
最終同期: 2026-08-14
時価総額
$1.67M
変化（1日）
-4.26%
変化（1年）
-43.21%
国
PL
取引 Adiuvo Investments S.A. (ADV)

カテゴリー

Healthcare
Adiuvo Investments S.A.（ADV）の収益
Aug 2026 時点の収益 TTM: 0
Adiuvo Investments S.A. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Adiuvo Investments S.A. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 $46.59B -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 $25.84B -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 $35.48B -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 $21.00B -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 $6.51B -
US